血清半乳糖凝集素-3 水平与非酒精性脂肪性肝病。
Serum galectin-3 levels in patients with nonalcoholic fatty liver disease.
机构信息
Department of Gastroenterology, Marmara University School of Medicine, 34899 Istanbul, Turkey.
出版信息
Clin Biochem. 2011 Aug;44(12):955-8. doi: 10.1016/j.clinbiochem.2011.05.015. Epub 2011 May 24.
OBJECTIVES
Galectin-3 might serve as a biomarker of human metabolic alterations. We measured serum levels of galectin-3 in patients with nonalcoholic fatty liver disease (NAFLD) and examined their association with clinical and histological phenotypes.
DESIGN AND METHODS
Serum levels of galectin-3 were assayed in 71 patients with biopsy-proven NAFLD and 39 controls.
RESULTS
Serum galectin-3 levels did not differ in patients with NAFLD (median 4.1 ng/mL; interquartile range: 1.5-5.5 ng/mL) compared with healthy controls (median 3.1 ng/mL; interquartile range: 0.8-7.5 ng/mL, P=0.93). Among patients with NAFLD, however, serum galectin-3 levels correlated significantly with BMI (r=0.267, P<0.05). This association persisted after adjustment for potential confounders (β=0.30; t=2.11, P<0.05).
CONCLUSIONS
Although galectin-3 was modestly associated with BMI, our results do not support the hypothesis that levels of this molecule are altered in patients with NAFLD.
目的
半乳糖凝集素-3 可能是人类代谢改变的生物标志物。我们测量了非酒精性脂肪性肝病（NAFLD）患者的血清半乳糖凝集素-3 水平，并研究了其与临床和组织学表型的关系。
设计和方法
在 71 例经活检证实的 NAFLD 患者和 39 名对照者中检测了血清半乳糖凝集素-3 水平。
结果
与健康对照组（中位数 3.1ng/mL；四分位间距：0.8-7.5ng/mL，P=0.93）相比，NAFLD 患者的血清半乳糖凝集素-3 水平无差异（中位数 4.1ng/mL；四分位间距：1.5-5.5ng/mL）。然而，在 NAFLD 患者中，血清半乳糖凝集素-3 水平与 BMI 呈显著相关（r=0.267，P<0.05）。调整潜在混杂因素后，这种相关性仍然存在（β=0.30；t=2.11，P<0.05）。
结论
尽管半乳糖凝集素-3 与 BMI 有一定的相关性，但我们的结果不支持该分子水平在 NAFLD 患者中改变的假说。
Zotero 插件